Section
A large EBMT study shows allo-HSCT provides favorable 2-year survival (65.7%) in high-risk t(6;9) AML, with superior outcomes in CR1 and pediatric/AYA patients. FLT3-ITD positivity triples relapse risk but doesn’t impact overall survi
Baseline ctDNA levels predict early progression and poor survival in untreated follicular lymphoma, outperforming traditional risk scores like FLIPI. This study highlights ctDNA’s potential as a stratification tool in clinical trials.
This review synthesizes the ASC4OPT trial results alongside pivotal evidence from the ASCEMBL and ASC4FIRST studies, evaluating the role of the STAMP inhibitor asciminib in chronic myeloid leukemia across multiple treatment lines.
VCAR33, a donor-derived anti-CD33 CAR T-cell therapy, demonstrated acceptable safety and preliminary efficacy in relapsed/refractory AML/MDS after allogeneic HCT, with 20% overall response rate and manageable toxicities.
This study uncovers clonal lymphocyte expansions and JAK-STAT pathway mutations as key drivers of refractory celiac disease, suggesting a shared pathogenic continuum between RCD1 and RCD2 while cautioning against JAK inhibitor monotherapy d
New research identifies P2Y14R as a key regulator of neutrophil-platelet aggregates and NET formation in venous thrombosis, with proglumide showing promise as a therapeutic antagonist.
The 2/20/20 risk stratification model identifies a smaller, truly high-risk SMM group with higher progression rates than the AQUILA trial criteria, suggesting better targeting for early intervention.
A groundbreaking study introduces reverse CAR T cells to selectively deplete anti-ADAMTS13 autoreactive B cells in immune-mediated thrombotic thrombocytopenic purpura (iTTP), offering a novel, precise, and potentially safer therapeutic appr
A novel genomic fusion breakpoint (GFB)-based MRD monitoring approach demonstrates superior sensitivity and specificity in pediatric ALL, addressing limitations of current IG/TCR-based methods, particularly in ETV6::RUNX1- and MEF2D-rearran
t(11;14) multiple myeloma exhibits slower MRD clearance but superior PFS with quadruplet therapy and MRD-adapted management, challenging conventional response kinetics paradigms.
Allogeneic hematopoietic stem cell transplantation offers a potential cure for blast-phase myeloproliferative neoplasms, with one-third of patients achieving long-term survival. Key factors influencing outcomes include TP53 mutations and pe
The HOVON110/ReBeL study compares R2 and R2B regimens in R/R FL, revealing comparable efficacy but higher toxicity with bendamustine addition. Despite low CT-based CR rates, R2B showed numerically better EFS and OS.
PRMT5 inhibition sensitizes B-cell lymphomas to ferroptosis by disrupting the PRMT5-ATF5-SLC7A11 axis, offering a novel therapeutic strategy for relapsed or refractory disease.
A novel statistical model predicts chronic immune thrombocytopenia (ITP) in children at diagnosis, using age, sex, immunoglobulin levels, and lab values, offering early clinical guidance.
In a phase 2 trial, amivantamab did not meet its primary response endpoint in recurrent/metastatic adenoid cystic carcinoma, but most patients achieved stable disease and toxicity was generally manageable.
A single-center retrospective study of 69 pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia reveals that TP53 alterations significantly compromise outcomes following tisagenlecleucel therapy. Pa
Researchers present a pioneering preemptive hematopoietic stem cell transplantation approach for RUNX1-FPD, a hereditary disorder carrying a 35-50% lifetime risk of blood cancer, introducing a shared decision-making framework to guide this
Researchers discovered that loss of GPRC5D, a key immunotherapy target in multiple myeloma, not only confers resistance to targeted therapies but actively promotes cancer cell proliferation and competitive fitness—creating a therapeutic par
A cross-sectional analysis of health technology assessments across G20 nations reveals significant disparities in access to CAR T-cell therapies, with only 48% of approved indications recommended for reimbursement and a median 1.54-year del
Researchers developed PRIME, a parsimonious risk stratification model for pancreatic ductal adenocarcinoma using electronic health record data. Validated across US health systems and the UK Biobank, PRIME retained 19 predictors and achieved
